Company Overview
Snapshot
Founded in October 2013, Cordio Medical operates with 11–50 employees and has raised $20.6M across 7 funding rounds from 7 investors.
Business overview
Cordio Medical develops groundbreaking, medical-grade solutions for monitoring various health conditions through speech analysis. Its core product, Cordio HearO™, is a smartphone-based application that utilizes sophisticated, proprietary algorithms and machine learning to analyze voice samples for near real-time monitoring and early detection of condition deterioration, particularly fluid accumulation related to Congestive Heart Failure (CHF). The system is patient-tailored, continuously learning the individual's voice to provide personalized and effortless monitoring. Cordio Medical serves the healthcare industry, focusing on chronic patients and providers, with the goal of identifying and mitigating condition worsening to prevent hospitalizations.
Strategic signal
In January 2024, Cordio Medical was highlighted for its Israeli app that detects heart failure weeks before an attack, showcasing the company's advanced AI capabilities in preventative healthcare. This development signals a significant step forward in non-invasive, early detection methods for chronic conditions, offering a critical window for timely intervention and potentially reducing healthcare burdens. For investors, this demonstrates the company's strong clinical validation and potential for market adoption in digital health.
Log in to access full profile ›Company Intelligence Q&A
- What clinical validation has Cordio Medical's HearO™ app received?
- In November 2023, Cordio Medical presented a study validating its voice signature AI tool for monitoring congestive heart failure during the American Heart Association's Scientific Sessions. The study demonstrated the app's ability to identify patients at risk of worsening heart failure, detecting 76.3% of events in the development group and 71.4% in the test group before they occurred.
- Which organizations are piloting Cordio Medical's HearO™ app in Spain?
- In October 2023, The General Hospital of Valencia and the Valencian Society of Cardiology began testing Cordio Medical’s HearO™ app, introduced by AstraZeneca in Spain, to monitor heart failure patients using voice biomarker AI.
- What was the outcome of Cordio Medical's clinical trial in Israel?
- In December 2022, Cordio Medical successfully conducted a trial of its HearO system among 180 patients across ten medical centers in Israel, detecting heart failure events an average of 18 days before they occurred.
- What was the funding amount raised in June 2022?
- In June 2022, Cordio Medical raised $18 million in a C Round funding round from Peregrine Ventures and Pix Vine Capital.